What's Next: Eastman Chemical Company, Gol Linhas Aereas Inteligentes SA, J.C. Penney Company, Inc., Tempur-Pedic International Inc.

Lakeway, NY -- (SBWIRE) -- 02/25/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Eastman Chemical Company (NYSE:EMN) shares jumped 4.32% and closed at $71.69 in the last trading session. The company, on Jan. 31, reported a fourth quarter net loss of $54 million or $0.35 per share, compared to net income of $12 million or $0.12 per share for the year-ago quarter. Adjusted earnings for the fourth quarter were $1.19 per share, compared to $0.78 per share in the prior year quarter. Analysts expected the company to earn $1.19 per share for the fourth quarter. Sales for the fourth quarter rose 26% to $2.17 billion from $1.72 billion in the same quarter last year. Analysts had a consensus revenue estimate of $2.24 billion for the fourth quarter.

Is EMN a Still a Buy after the Solid momentum? Let’s Find out Here

Gol Linhas Aereas Inteligentes SA (ADR) (NYSE:GOL) shares gained 4.29% to $6.57. The company, on Feb. 13, announced that on February 7, 2013, it priced at 10.75% an offer of USD 200 million in senior notes with maturity in 2023. The Company is guarantor of notes issued by its subsidiary VRG Linhas Aereas SA.

Additionally, the company, prior last week, also announced that on February 8, 2013, its Board of Directors authorized administrators of Smiles SA, a subsidiary of the Company, to take the measures required to apply for the registration as a public company and the carry out of an initial public offering (IPO) before the Securities Commission CVM, as well as to take other formal steps applicable to the operation. The Company will keep the market updated on the issue.

Is GOL a Strong Buying Opportunity After The Recent Slump? Find out Here

J.C. Penney Company, Inc. (NYSE:JCP) shares gained 4.27% to $22.47. Equities research analysts at JPMorgan Chase decreased their price target on shares of J.C. Penney from $20.00 to $18.00 in a research note issued to investors last week. The firm currently has a “neutral” rating on the stock.

Additionally, the company’s shareholders appear to be at an increased risk of a dilutive convertible offering under terms of an amended credit agreement, argue Credit Suisse analysts last week.

Should JCP Buy JCP After The Recent Movement? Let’s Find out Here

Tempur-Pedic International Inc. (NYSE:TPX) shares jumped 4.25% and closed at $37.05. The company, on Feb. 4, announced the appointment of W. Timothy Yaggi as Chief Operating Officer. Mr. Yaggi will report to Mark Sarvary, President and CEO. The appointment of Mr. Yaggi as COO--a new role at Tempur-Pedic--underscores the company's ongoing commitment to carry out its strategic growth plan and prepare for the evolution of its business, brands and product lines.

Additionally, TPX’s stock was upgraded by KeyBanc from a “hold” rating to a “buy” rating in a research note issued last month. The firm currently has a $48.00 price target on the stock.

Is TPX a Strong Buying Opportunity After The Recent Slump? Find out Here

About ThePennyStockProfiler.com
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com

Disclaimer
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.